Table 4.

All-cause mortality (excluding suicide), cardiac mortality, and sudden cardiac death: current antipsychotic use versus nonuser psychiatric.

Outcome	Treatment	Number of events	PY	Incidence rate per 1000 PY (95% CI)	Fully adjusted RR (aRR) (95% CI)
All-cause mortality	Nonuser psychiatric	7765	307,276	25.3 (24.7–25.8)	Reference
	Amisulpride	503	5220	96.4 (88.1–105.2)	1.51 (1.37–1.66)‡
	Chlorpromazine	1553	28,550	54.4 (51.7–57.2)	1.59 (1.49–1.69)‡
	Haloperidol	5552	21,045	263.8 (256.9–270.9)	2.33 (2.12–2.56)‡
	Olanzapine	1305	34,985	37.3 (35.3–39.4)	1.04 (0.93–1.17)
	Perphenazine	260	8507	30.6 (27.0–34.5)	1.30 (0.91–1.85)
	Quetiapine	1887	17,216	109.6 (104.7–114.7)	1.42 (1.34–1.50)‡
	Risperidone	3600	33,917	106.1 (102.7–109.7)	1.64 (1.56–1.72)‡
Cardiac mortality	Nonuser psychiatric	1289	200,988	6.4 (6.1–6.8)	Reference
	Amisulpride	98	3936	24.9 (20.2–30.3)	2.50 (1.76–3.57 )‡
	Chlorpromazine	161	15,220	10.6 (9.0–12.3)	1.70 (1.11–2.58) )†
	Haloperidol	522	11,546	45.2 (41.4–49.3)	2.10 (1.59–2.77) ‡
	Olanzapine	206	26,765	7.7 (6.7–8.8)	1.53 (1.12– 2.09) ‡
	Perphenazine	22	3232	6.8 (4.3–10.3)	0 (NC)
	Quetiapine	344	15,183	22.7 (20.3–25.2)	1.79 (1.38–2.33) ‡
	Risperidone	543	25,024	21.7 (19.9–23.6)	1.87 (1.44 –2.41)‡
Sudden cardiac death (secondary definition)	Nonuser psychiatric	98	23,873	4.1 (3.3–5.0)	Reference
	Amisulpride	15	674	22.3 (12.5–36.7)	0 (NC)
	Chlorpromazine	10	1297	7.7 (3.7–14.2)	0 (NC)
	Haloperidol	47	1236	38.0 (28.0–50.6)	4.33 (3.03–6.17)‡
	Olanzapine	10	3454	2.9 (1.4–5.3)	0 (NC)
	Perphenazine	0	221	0.0 (0.0–16.7)	0 (NC)
	Quetiapine	46	3407	13.5 (9.9–18.0)	1.51 (1.04–2.19)†
	Risperidone	17	2187	7.8 (4.5–12.4)	0 (NC)

*P < 0.10; ^† P < 0.05; ^‡ P < 0.01.

Abbreviations: aRR: adjusted relative risk; CI: confidence interval; NC: not calculated; PY: person-years.